Back

Dapagliflozin effect on cardiopulmonary function, reverse cardiac remodelling and biomarkers in a cohort of HFrEF patients

12 May 2024 (09:00 - 09:45)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 1 Treatment HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Irene Mattavelli

Monzino Cardiology Centre, Milan (Italy)

7 More presentations in this session

Presentation thumbnail
Effects of left atrial to coronary sinus shunting on right heart function: the ALT-FLOW early feasibility study (EFS) one-year results
Associate Professor M. Urey (San Diego, US)
Abstract Slides Video
Presentation thumbnail
The efficacy and safety of heart failure treatment according to frailty status; a systematic review.
Miss C. Nijskens (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Heart failure in elderly patients with a recent myocardial infarction and the effect of omega-3 fatty acids: secondary analysis from the OMEMI trial
Doctor K. Berge (Nordbyhagen, NO)
Abstract Slides Video
Presentation thumbnail
First-in-human study of left ventricular remuscularization with induced pluripotent stem cell derived cardiomyocyte spheroids for severe ischemic heart failure patients: preliminary LAPiS study result
Assistant Professor Y. Ichihara (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Cardiac rhythm management devices in patients with heart failure - preliminary results of the DIRECT HF international survey on healthcare professionals' educational needs
Professor S. Zieroth (Winnipeg, CA)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - treatment 1

The Event

Event poster

Heart Failure 2024

12 May 2024 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Dapagliflozin's influence on cardiac remodeling in chronic heart failure patients
thumbnail
Congress Session
Further Insights into SGLT2i treatment for heart failure
thumbnail
Congress Presentation
Dapagliflozin versus empagliflozin in patients with heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources